Temptime Corporation has announced today that its board of directors has promoted President Renaat Van den Hooff to chief executive officer.

Mr. Van den Hooff has served as president of Temptime since 2011.

Chairman of Temptime Corporation said Curt Selquist said: "Renaat deeply values Temptime’s mission of improving global health and has done an outstanding job of expanding Temptime’s products and services to organisations that are saving lives around the world.

"Renaat leads by example and has cultivated a highly talented team of employees who are focused on delivering results and developing the next generation of technology to meaningfully improve health care."

Under Mr. Van den Hooff’s leadership, Temptime has expanded its capabilities to the world’s largest health organisations and pharmaceutical corporations. The company has broadened its portfolio of devices, which monitor the temperature of vaccines and prescription drugs to blood and other biological products.

Mr. Van den Hooff also spearheaded an expansion of Temptime’s operations, which doubled the company’s production capacity. He is currently leading initiatives to develop new technologies and extend Temptime’s presence into China and other markets.

Mr. Van den Hooff said: "I am proud of Temptime’s recent accomplishments and performance, and want to thank the executive team and our employees for their continued passion and commitment to our mission.

"It is exciting to lead Temptime in expanding its services and developing new technologies that will support the safe storage and distribution of a wide range of medical products across the globe."

Mr. Van den Hooff has more than 30 years of global health care leadership experience. Prior to joining Temptime, he was worldwide president of Johnson & Johnson’s joint venture with Merck. He also held management positions with Johnson & Johnson in Belgium, the United Kingdom and the United States.

In addition, he received a degree in economics from VEH in Brussels and a master’s degree in marketing from the Vlerick Business School at the University of Ghent in Belgium. He serves as vice-chairman of the board of a leading chapter of the National Multiple Sclerosis Foundation.